Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Author Correction: Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer.

Heumann A, Kaya Ö, Burdelski C, Hube-Magg C, Kluth M, Lang DS, Simon R, Beyer B, Thederan I, Sauter G, Izbicki JR, Luebke AM, Hinsch A, Jacobsen F, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Schlomm T, Wilczak W.

Sci Rep. 2018 Aug 21;8(1):12821. doi: 10.1038/s41598-018-30975-9.

2.

Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours.

Mills L, Drymousis P, Vashist Y, Burdelski C, Prachalias A, Srinivasan P, Menon K, Cotoi C, Khan S, Cave J, Armstrong T, Weickert MO, Izbicki J, Schrader J, Frilling A, Ramage JK, Srirajaskanthan R.

Endocr Connect. 2017 Nov;6(8):876-885. doi: 10.1530/EC-17-0293.

3.

IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues.

Burdelski C, Jakani-Karimi N, Jacobsen F, Möller-Koop C, Minner S, Simon R, Sauter G, Steurer S, Clauditz TS, Wilczak W.

Oncol Rep. 2018 Jan;39(1):3-12. doi: 10.3892/or.2017.6072. Epub 2017 Nov 2.

4.

Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers.

Person F, Wilczak W, Hube-Magg C, Burdelski C, Möller-Koop C, Simon R, Noriega M, Sauter G, Steurer S, Burdak-Rothkamm S, Jacobsen F.

Tumour Biol. 2017 Oct;39(10):1010428317712166. doi: 10.1177/1010428317712166.

PMID:
29022485
5.

High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.

Burdelski C, Shihada R, Hinsch A, Angerer A, Göbel C, Friedrich E, Hube-Magg C, Burdak-Rothkamm S, Kluth M, Simon R, Möller-Koop C, Sauter G, Büscheck F, Wittmer C, Clauditz TS, Krech T, Tsourlakis MC, Minner S, Graefen M, Schlomm T, Wilczak W, Jacobsen F.

Prostate. 2017 Nov;77(15):1528-1538. doi: 10.1002/pros.23431. Epub 2017 Sep 19.

PMID:
28929505
6.

Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.

Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG.

Cell Rep. 2017 Jun 6;19(10):2045-2059. doi: 10.1016/j.celrep.2017.05.049.

7.

Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer.

Heumann A, Kaya Ö, Burdelski C, Hube-Magg C, Kluth M, Lang DS, Simon R, Beyer B, Thederan I, Sauter G, Izbicki JR, Luebke AM, Hinsch A, Jacobsen F, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Schlomm T, Wilczak W.

Sci Rep. 2017 May 17;7(1):2056. doi: 10.1038/s41598-017-02279-x. Erratum in: Sci Rep. 2018 Aug 21;8(1):12821.

8.

Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.

Burdelski C, Borcherding L, Kluth M, Hube-Magg C, Melling N, Simon R, Möller-Koop C, Weigand P, Minner S, Haese A, Michl HU, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C, Lebok P, Steurer S, Izbicki JR, Sauter G, Krech T, Büscheck F, Clauditz T, Schlomm T, Wilczak W.

Oncotarget. 2017 May 9;8(19):31494-31508. doi: 10.18632/oncotarget.16357.

9.

Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.

Burdelski C, Fitzner M, Hube-Magg C, Kluth M, Heumann A, Simon R, Krech T, Clauditz T, Büscheck F, Steurer S, Wittmer C, Hinsch A, Luebke AM, Jacobsen F, Minner S, Tsourlakis MC, Beyer B, Steuber T, Thederan I, Sauter G, Izbicki J, Schlomm T, Wilczak W.

Neoplasia. 2017 Apr;19(4):279-287. doi: 10.1016/j.neo.2017.01.005. Epub 2017 Mar 8.

10.

p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.

Burdelski C, Dieckmann T, Heumann A, Hube-Magg C, Kluth M, Beyer B, Steuber T, Pompe R, Graefen M, Simon R, Minner S, Tsourlakis MC, Koop C, Izbicki J, Sauter G, Krech T, Schlomm T, Wilczak W, Lebok P.

Tumour Biol. 2016 Sep;37(9):12655-12663. Epub 2016 Jul 21.

PMID:
27444279
11.

Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.

Burdelski C, Kleinhans S, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wilczak W, Marx A, Sauter G, Wittmer C, Huland H, Simon R, Schlomm T, Steurer S.

Int J Cancer. 2016 Mar 1;138(5):1199-206. doi: 10.1002/ijc.29860. Epub 2015 Oct 1.

12.

The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.

Burdelski C, Menan D, Tsourlakis MC, Kluth M, Hube-Magg C, Melling N, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Simon R, Schlomm T, Steurer S, Krech T.

BMC Cancer. 2015 Jul 23;15:538. doi: 10.1186/s12885-015-1555-8.

13.

Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers.

Burdelski C, Bujupi E, Tsourlakis MC, Hube-Magg C, Kluth M, Melling N, Lebok P, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Wilczak W, Simon R, Schlomm T, Steurer S, Krech T.

PLoS One. 2015 Jun 1;10(6):e0128525. doi: 10.1371/journal.pone.0128525. eCollection 2015.

14.

Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer.

Burdelski C, Reiswich V, Hube-Magg C, Kluth M, Minner S, Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wittmer C, Huland H, Simon R, Schlomm T, Sauter G, Steurer S.

Clin Cancer Res. 2015 Aug 1;21(15):3471-9. doi: 10.1158/1078-0432.CCR-14-0620. Epub 2015 Apr 29.

15.

HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy.

Zabalza CV, Adam M, Burdelski C, Wilczak W, Wittmer C, Kraft S, Krech T, Steurer S, Koop C, Hube-Magg C, Graefen M, Heinzer H, Minner S, Simon R, Sauter G, Schlomm T, Tsourlakis MC.

Oncotarget. 2015 May 20;6(14):12822-34.

16.

An 18 kDa scaffold protein is critical for Staphylococcus epidermidis biofilm formation.

Decker R, Burdelski C, Zobiak M, Büttner H, Franke G, Christner M, Saß K, Zobiak B, Henke HA, Horswill AR, Bischoff M, Bur S, Hartmann T, Schaeffer CR, Fey PD, Rohde H.

PLoS Pathog. 2015 Mar 23;11(3):e1004735. doi: 10.1371/journal.ppat.1004735. eCollection 2015 Mar.

17.

HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer.

Burdelski C, Ruge OM, Melling N, Koop C, Simon R, Steurer S, Sauter G, Kluth M, Hube-Magg C, Minner S, Wittmer C, Wilczak W, Hinsch A, Lebok P, Izbicki JR, Heinzer H, Graefen M, Huland H, Schlomm T, Krech T.

Exp Mol Pathol. 2015 Jun;98(3):419-26. doi: 10.1016/j.yexmp.2015.03.024. Epub 2015 Mar 18.

PMID:
25794974
18.

Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer.

Burdelski C, Strauss C, Tsourlakis MC, Kluth M, Hube-Magg C, Melling N, Lebok P, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Krech T, Sauter G, Wilczak W, Simon R, Schlomm T, Steurer S.

Oncotarget. 2015 Apr 10;6(10):8377-87.

19.

Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.

Burdelski C, Barreau Y, Simon R, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Sauter G, Wittmer C, Steurer S, Adam M, Huland H, Schlomm T, Tsourlakis MC, Quaas A.

Hum Pathol. 2015 Apr;46(4):514-23. doi: 10.1016/j.humpath.2014.06.006. Epub 2014 Jun 26.

PMID:
25701228
20.

βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma.

Quaas A, Rahvar AH, Burdelski C, Koop C, Eichelberg C, Rink M, Dahlem R, Schlomm T, Tsourlakis MC, Simon R, Minner S, Sauter G, Steurer S.

World J Urol. 2015 Oct;33(10):1561-9. doi: 10.1007/s00345-014-1463-6. Epub 2014 Dec 21.

PMID:
25527909

Supplemental Content

Loading ...
Support Center